Nektar Therapeutics develops and enables differentiated therapeutics with its industry-leading pulmonary and PEGylation technology platforms. Nektar’s capabilities have enabled nine approved products for partners, including the world’s leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its platforms to existing medicines with the objective to enhance efficacy, safety and compliance.